Sanofi records €1B+ write-off, ends work on two immunology assets
Sanofi booked over €1.03 billion in impairment charges in the second quarter largely due to an eczema drug termination, with its pipeline review leading to the wind-down of two other immunology drugs. The impairment loss ...
July 30, 2026 05:35 AM EDT R&DPharma Sanofi records €1B+ write-off, ends work on two immunology assets Ayisha Sharma News Reporter Sanofi booked over €1.03 billion in impairment charges in the second quarter largely due to an eczema drug termination, with its pipeline review leading to … Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox. SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER
comments(0)
5-min edit window · permanent after that